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Abstract
Background: The association of serum bilirubin con-
centrations with kidney function and albuminuria has
not been established in the US general population.
Methods: We performed a cross-sectional analysis of
data from the National Health and Nutrition Exami-
nation Survey (NHANES) 2001–2006 and examined
the associations of serum total bilirubin concentra-
tions with estimated glomerular filtration rate (eGFR)
and albuminuria in a nationally representative sample
of 13,184 adults aged 20 years or older. eGFR was
estimated using the abbreviated Modification of Diet
in Renal Disease equation. Urinary albumin excretion
was measured using the albumin/creatinine ratio.
Results: An eGFR -60 mL/min/1.73 m2 and urinary
albumin/creatinine ratio G30 mg/g were present in
8.1% (ns1072) and 10.6% (ns1402) of participants,
respectively. A total of 427 (3.2%) individuals had a
serum total bilirubin concentration )22.23 mmol/L.
After adjustment for demographics, comorbidities,
alcohol consumption, viral hepatitis status and other
laboratory measures, serum bilirubin was negatively
associated with eGFR, and positively with albumin-
uria both in the whole cohort and in the subgroup of
non-diabetic individuals. In contrast, serum bilirubin
was not significantly associated with eGFR or albu-
minuria in persons with diabetes (ns1253).
Conclusions: Increasing serum concentrations of total
bilirubin are independently associated with decreas-
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ing eGFR and increasing albuminuria in the US adult
population.
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Introduction
The prevalence of chronic kidney disease (CKD) is
increasing worldwide (1, 2). Reduced estimated glo-
merular filtration rate (eGFR) and abnormal albumin-
uria have been associated with increased risk of
end-stage renal disease, cardiovascular disease and
other comorbidities (3–6). Because kidney disease
often progresses to end-stage renal disease, the iden-
tification of precursors and risk factors for kidney
disease progression are essential, with the belief
that interventions will prevent or delay progression to
kidney failure.
Increased concentrations of serum bilirubin have
long been used as a marker of liver dysfunction. In
addition, serum bilirubin has been shown to be
inversely related to cardiovascular disease, suggest-
ing a potentially athero-protective effect of bilirubin
(7–10). However, the relationship of serum bilirubin
with the future risk of cardiovascular events appears
to be more complex. A U-shaped relationship was
observed between serum bilirubin and risk of major
ischemic heart disease events in a prospective study
of 7685 middle-aged British men who were followed
for 11.5 years (11). It is also known that serum bili-
rubin concentrations are significantly higher in men
than in women, and tend to decline with advancing
age in both sexes (12).
Information on the association of serum bilirubin
concentrations with kidney function and albuminuria
is limited and controversial. Fukui et al. found that
serum total bilirubin was positively associated with
eGFR, and negatively with albuminuria in a hospital-
based sample of 633 Japanese type 2 diabetic
patients (13). These results suggest a potential reno-
protective effect of bilirubin. In contrast, we found
that higher serum total bilirubin was significantly
associated with lower eGFR in both non-diabetic and
diabetic individuals in 2678 unselected outpatients
35 years or age or older (14).
To date, the association of serum bilirubin concen-
trations with kidney function and albuminuria have
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not been established in the US general population.
We, therefore, examined the association of serum bili-
rubin concentrations with kidney function measures
in the National Health and Nutrition Examination Sur-
vey (NHANES) 2001–2006, a nationally representative
cross-sectional examination of the US adult civilian
population.
Materials and methods
Study population
The NHANES is a program designed to assess the health and
nutritional status of the US civilian non-institutionalized
population. The study was approved by the National Center
for Health Statistics (NCHS) Institutional Review Board and
all subjects gave informed consent (15). The NHANES exam-
inations were conducted from 2001 to 2006 in three phases
(2001–2002, 2003–2004 and 2005–2006), and data from these
phases were combined for the purpose of this analysis,
following NCHS analytical guidelines (16).
In all phases of NHANES, a stratified, multistage sampling
design was used, with over-sampling of non-Hispanic blacks,
Mexican-Americans and persons over the age of 60 years.
Individuals participated in an interview conducted at home,
as well as an extensive physical examination performed at
a mobile examination center, which included blood and
urine collection (17). This analysis was initially restricted to
13,213 adults 20 years of age or older. However, responders
who had a missing serum bilirubin and incomplete infor-
mation on the main covariates of interest were excluded
from analysis (ns29). Thus, 13,184 adults constituted the
sample used in this analysis.
Study variables
After collection of fasting, venous blood samples were
immediately centrifuged. Specimens were then frozen and
shipped weekly to a central laboratory where they were ini-
tially stored at –208C, and then at –708C (16, 17). Serum total
bilirubin was determined by automated biochemical profil-
ing (Beckman Synchron LX20, Beckman Coulter, Fullerton,
CA, USA); fractionation of bilirubin was not performed. The
LX20 uses a timed-endpoint Diazo method to measure the
concentration of serum total bilirubin. The analytical range
for this assay is 1.71–513 mmol/L (0.1–30 mg/dL), and the
reference range is 3.42–22.23 mmol/L (0.2–1.3 mg/dL). Both
intra- and inter-assay coefficients of variation were -3%
(16).
eGFR was derived from the re-expressed MDRD equa-
tions175.0=(serum creatinine value)–1.154=age–0.203=0.742
(if female)=1.21 (if black) (18). Values that exceeded 200
mL/min/1.73 m2 were truncated. Serum creatinine was meas-
ured using the Jaffe´ method (kinetic alkaline picrate) with a
Beckman Synchron LX20 (16, 19). As reported in the
NHANES laboratory procedure manual, hemolysis, lipemia
and bilirubin -34.2 mmol/L (-2 mg/dL) have no significant
interference with the measurement of serum creatinine. At
bilirubin levels )51.3 mmol/L ()3 mg/dL), the creatinine
value is decreased by 6.84 mmol/L (0.4 mg/dL). Other poten-
tial interfering substances (e.g., cefoxitin, cefaclor, glutha-
thione, acetoacetic acid, L-DOPA methyl ester) are reported
in detail in the laboratory procedures manual (16, 19). Both
intra- and inter-assay coefficients of variation were -3.5%.
As recommended by NHANES analytic guidelines (19),
NHANES serum creatinine values in 2005–2006 were adjust-
ed to ensure comparability with standard creatinine using
the following formula: standard creatinine (mg/dL)s–0.016q
0.978=(NHANES 2005–2006 uncalibrated serum creatinine
wmg/dLx). However, a recent calibration study in which the
original serum creatinine measurements (Jaffe´ method) in
NHANES 2001–2002, and 2003–2004 were compared with
standard creatinine measured using an assay traceable to
known gold-standard methods implemented at the Cleve-
land Clinic Research Laboratory demonstrated that no cor-
rection was needed for serum creatinine concentrations
measured in NHANES 2001–2004 (20). In particular, the
Cleveland Clinic Research laboratory analyzed the serum
creatinine specimens using a Roche coupled enzymatic
assay (creatininase, creatinase, sarcosine oxidase, kits
1775677 and 1775766) performed on a Roche P Module
instrument (Roche Diagnostics, Basel, Switzerland). The
Roche method calibrators were traceable to an isotope dilu-
tion mass spectrometric method for serum creatinine using
standard references methods (NIST-SRM 967). They were
also confirmed by analysis of CAP LN-24 linearity set based
on National Institute of Standards and Technology (NIST)
assigned values (20).
Urinary albumin excretion was measured using a fluores-
cent immunoassay (Sequoia-Turner model 450 digital fluo-
rometer, Block Scientific, Holbrook, NY, USA) on the basis
of the spot urine albumin/creatinine ratio. Both intra- and
inter-assay coefficients of variation were -9% (16). Abnor-
mal albuminuria was defined as albumin/creatinine ratio
G30 mg/g (18).
Serum concentrations of total cholesterol, high-density
lipoprotein (HDL) cholesterol, triglycerides, alanine amino-
transferase (ALT), aspartate aminotransferase (AST) and g-
glutamyltransferase (GGT) were measured enzymatically
with a Hitachi-704 Analyzer (Roche Diagnostics, Indianapolis,
IN, USA) (16). Low-density lipoprotein (LDL) cholesterol was
calculated using the Friedewald’s equation, except when tri-
glycerides exceeded 4.55 mmol/L. Exposure to hepatitis C
virus (HCV) was determined by presence of antibody to HCV,
and hepatitis B infection was identified by the presence of
hepatitis B core antibody (16). Serum glucose was measured
using a modified hexokinase enzymatic method, and a radio-
immunoassay method was used to measure serum insulin
(16). Homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated using fasting glucose and insulin
measurements as follows w(fasting insulin (mU/mL)=fasting
glucose (mmol/L))/22.5x (21). HOMA-IR score was available
in non-diabetic individuals.
Self-reported race was defined as non-Hispanic white,
non-Hispanic black, Mexican-American, or other. A diagnosis
of hypertension was assigned if the subject reported a phy-
sician diagnosis of hypertension, if the subject reported
taking prescription medications for hypertension, or if the
systolic blood pressure was G140 mm Hg or the diastolic
blood pressure was G90 mm Hg. Participants were defined
as having diabetes if they were taking hypoglycemic drugs,
had a fasting plasma glucose concentration G7 mmol/L or if
a physician told them that they had diabetes. Smoking status
was classified as never smoked, ex-smoker or current smok-
er. Alcohol consumption was recorded as number of drinks
per day. Body mass index (BMI) was calculated as weight in
kilograms divided by the square of height in meters. Waist
circumference was measured with a steel measuring tape to
the nearest 0.1 cm at the high point of the iliac crest at
minimal respiration (16).
Statistical analysis
NHANES uses a complex, multistage, probability-sampling
design to select participants that are representative of the
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Table 1 Age-gender standardized baseline demographics, comorbidities and laboratory results according to eGFR in the
entire cohort (ns13,184).
eGFR G90 mL/min/1.73 m2 60–89 mL/min/1.73 m2 -60 mL/min/1.73 m2 p-Value
Characteristics
ns6987 ns5125 ns1072 for trend
Age, years 38 (14) 52 (16) 71 (10) -0.0001
Gender, % 0.01
Males 47.4 48.9 36.4
Females 52.6 51.1 63.6
Ethnicity, % -0.0001
Non-Hispanic white 39.3 65.1 71.2
Non-Hispanic black 24.7 15.0 14.0
Mexican-American 31.5 16.5 11.3
Other 4.5 3.4 3.5
Smoking status, % -0.0001
Never 53.4 51.1 50.9
Prior 18.8 27.9 38.5
Current 27.8 21.0 10.6
Hypertension, % 19.5 34.5 68.1 -0.0001
Diabetes, % 6.5 8.4 23.7 -0.0001
Alcohol drinks per day, % -0.0001
0 36.1 36 57.6
1–3 44.8 51.9 39.7
)3 19.1 12.1 2.7
Measurements
BMI, kg/m2 28 (7) 29 (6) 29 (5) 0.001
Waist circumference, inches 38 (7) 39 (6) 40 (5) -0.0001
Glucose, mmol/L 5.28 (1.8) 5.44 (1.8) 6.11 (2.0) -0.0001
Total cholesterol, mmol/L 5.12 (1.1) 5.26 (1.1) 5.25 (1.1) -0.0001
LDL cholesterol, mmol/L 2.96 (0.9) 3.01 (0.9) 2.98 (0.8) 0.0005
HDL cholesterol, mmol/L 1.38 (0.4) 1.38 (0.4) 1.37 (0.4) 0.27
Triglycerides, mmol/L 1.66 (1.8) 1.70 (1.4) 1.93 (1.0) 0.0003
AST, U/L 25 (23) 25 (13) 26 (11) 0.60
ALT, U/L 26 (26) 25 (15) 22 (11) 0.001
GGT, U/L 29 (55) 30 (34) 30 (47) 0.17
Total bilirubin, mmol/L 12.3 (5.4) 12.8 (4.6) 13.0 (6.8) -0.0001
Glycosylated hemoglobin, % 5.5 (1.0) 5.6 (0.9) 5.9 (0.9) -0.0001
HOMA-IR score 3.3 (3.4) 3.5 (3.9) 4.8 (5.2) -0.0001
Albuminuria, % 8.1 10.0 30.1 -0.0001
Hepatitis B antibody, % 20.5 16.1 11.5 -0.0001
Hepatitis C antibody, % 1.0 0.9 0.5 0.20
Results are expressed as means ("SD) or percentages. ALT, alanine aminotransferase; AST, aspartate aminotransferase;
BMI, body mass index; GGT, g-glutamyltransferase; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment
of insulin resistance; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate.
civilian, non-institutionalized US population. All analyses
accounted for the complex sampling method. Analyses were
performed with SAS version 9.1 (SAS Institute Inc., Cary, NY,
USA) callable SUDAAN version 9.01 (Research Triangle Insti-
tute, Research Triangle Park, NC, USA).
Results are expressed as mean"SD or percentages. For
statistical purposes (Tables 1 and 2), participants were strat-
ified into categories of eGFR (i.e., -60, 60–89 and G90
mL/min/1.73 m2) and albuminuria (classified as normal and
abnormal, i.e., albumin/creatinine ratio G30 mg/g). In these
analyses, we combined subjects with eGFR 15–30 mL/min/
1.73 m2 and those with eGFR 30–59 mL/min/1.73 m2 into a
single eGFR category due to the low number of individuals
(ns66) with eGFR values of 15–30 mL/min/1.73 m2.
Statistical analyses included one-way analysis of variance
(for continuous variables) and the x2-test with Yates’s cor-
rection for continuity (for categorical measures). Skewed
variables (triglycerides and HOMA-IR score) were logarith-
mically transformed to improve normality prior to analysis.
The association between serum bilirubin and eGFR
(included as continuous variable) was investigated using
linear (unadjusted and fully adjusted) regression models in
the whole group and in subgroups of participants stratified
by diabetes status (Table 3). We excluded subjects who
had a serum creatinine concentration )176.8 mmol/L ()2.0
mg/dL) or serum bilirubin concentrations )22.23 mmol/L
()1.3 mg/dL) (ns513). The covariates included in fully-
adjusted regression models were age, gender, race/ethnicity,
smoking status, hypertension, diabetes, BMI, waist circum-
ference, total cholesterol, LDL-cholesterol, HDL-cholesterol,
triglycerides, alcohol consumption, viral hepatitis markers,
glycosylated hemoglobin, HOMA-IR score and albuminuria.
The association between serum bilirubin and albuminuria
(included as categorical variable) was investigated using
logistic regression models in the whole group, excluding
subjects who had a serum creatinine )176.8 mmol/L ()2.0
mg/dL) or serum bilirubin )22.23 mmol/L ()1.3 mg/dL)
(ns513), and in subgroups of participants stratified by
diabetes status (Table 4). The covariates included in fully-
adjusted regression models were age, gender, race/ethnicity,
smoking status, hypertension, diabetes, BMI, waist circum-
ference, total cholesterol, LDL-cholesterol, HDL-cholesterol,
triglycerides, alcohol consumption, viral hepatitis markers,
glycosylated hemoglobin, insulin resistance and eGFR.
In all regression models, observations were weighted to
reflect the general US population as of the early 2000s, using
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Table 2 Age-gender standardized baseline demographics, comorbidities and laboratory results according to urinary albumin
excretion in the entire cohort (ns13,184).
Urine albumin/creatinine ratio, mg/g -30 G30 p-Value
Characteristics
ns11,652 ns1532 for difference
Age, years 44 (17) 54 (17) -0.0001
Gender, % 0.002
Males 47.8 43.3
Females 52.2 56.7
Ethnicity, % -0.0001
Non-Hispanic white 51.3 42.8
Non-Hispanic black 20.0 25.3
Mexican-American 24.7 27.3
Other 4.0 4.6
Smoking status, % 0.14
Never 52.8 49.3
Prior 22.9 26.4
Current 24.3 24.3
Hypertension, % 25.2 50.6 -0.0001
Diabetes, % 6.0 26.6 -0.0001
Alcohol drinks per day, % -0.0001
0 35.8 47.0
1–3 48.2 39.9
)3 16.0 13.1
eGFR, %, mL/min/1.73 m2 -0.0001
G90 59.1 46.2
60–89 36.7 36.0
-60 4.2 17.8
Measurements
BMI, kg/m2 28 (6) 30 (8) -0.0001
Waist circumference, inches 38 (6) 40 (6) -0.0001
Glucose, mmol/L 5.22 (1.5) 6.61 (3.2) -0.0001
Total cholesterol, mmol/L 5.18 (1.1) 5.26 (1.2) 0.03
LDL cholesterol, mmol/L 2.97 (0.9) 3.02 (0.9) 0.02
HDL cholesterol, mmol/L 1.38 (0.4) 1.36 (0.4) 0.13
Triglycerides, mmol/L 1.65 (1.5) 2.04 (2.3) -0.0001
AST, U/L 25 (19) 26 (14) 0.24
ALT, U/L 26 (22) 25 (15) 0.05
GGT, U/L 29 (39) 40 (81) -0.0001
Total bilirubin, mmol/L 12.4 (4.9) 12.3 (6.3) 0.40
Glycosylated hemoglobin, % 5.5 (0.8) 6.3 (1.7) -0.0001
HOMA-IR score 3.3 (3.4) 5.1 (5.8) -0.0001
Hepatitis B antibody, % 18.5 16.4 0.06
Hepatitis C antibody, % 0.9 1.5 0.02
Results are expressed as means ("SD) or percentages. eGFR, estimated glomerular filtration rate; ALT, alanine aminotrans-
ferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, g-glutamyltransferase; HDL, high-density lipoprotein;
HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein.
weights calculated for that purpose by the National Health
Statistics (17). p-Values -0.05 were considered significant.
Results
Among the 13,184 adult participants, the mean serum
total bilirubin was 12.48 ("5.3) mmol/L, the median
was 12.0 (inter-quartile range 10.26–13.68) mmol/L. A
total of 427 (3.2%) persons had a serum bilirubin
concentration )22.23 mmol/L ()1.3 mg/dL). An eGFR
-60 mL/min/1.73 m2 or albumin/creatinine ratio
G30 mg/g were present in 8.1% (ns1072) and 10.6%
(ns1402) of the whole sample, respectively.
The clinical and biochemical characteristics of par-
ticipants stratified by eGFR categories are summa-
rized in Table 1. Compared with those with normal or
near-normal eGFR, persons with lower eGFR were
older, more likely to be female, more likely to be non-
Hispanic white, and had greater prevalence of hyper-
tension, diabetes and abnormal albuminuria, and
higher values of BMI, waist circumference, serum
glucose, glycosylated hemoglobin, insulin resistance,
total cholesterol, LDL-cholesterol, triglycerides, and
total bilirubin concentrations. Moreover, participants
with lower eGFR also had lower serum ALT activity
and were less likely to report alcohol consumption
and a lower prevalence of hepatitis B seropositivity.
When participants were stratified by categories of
albuminuria (Table 2), the results remained essential-
ly unchanged with a single important exception, i.e.,
no significant differences were found in serum bili-
rubin concentrations between participants with nor-
mal and those with abnormal albuminuria. Moreover,
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Table 3 Association of serum bilirubin concentrations with eGFR in NHANES participants.
b (95% CI) Standardized b t-Value p-Value
Whole cohort (ns13,184)
Unadjusted –8.35 (–9.79 to –6.91) –0.10 –11.4 -0.0001
Multivariate adjusteda –3.40 (–4.71 to –2.09) –0.04 –5.12 -0.0001
Excluding participants with a
serum creatinine )2.0 mg/dL or
bilirubin )1.3 mg/dL (ns12,671)
Unadjusted –16.22 (–18.30 to –14.14) –0.14 –15.3 -0.0001
Multivariate adjusteda –8.41 (–10.35 to –6.47) –0.07 –8.51 -0.0001
Non-diabetics (ns11,931)
Unadjusted –9.35 (–10.82 to –7.88) –0.11 –12.50 -0.0001
Multivariate adjustedb –4.12 (–5.45 to –2.79) –0.05 –6.09 -0.0001
Diabetics (ns1253)
Unadjusted 1.61 (–4.88 to 8.10) 0.01 0.5 0.63
Multivariate adjustedc 2.06 (–5.07 to 9.19) 0.01 0.6 0.57
aAdjusted for age, gender, race/ethnicity, smoking, hypertension, diabetes, body mass index, waist circumference, total cho-
lesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, alcohol consumption, viral hep-
atitis markers, glycosylated hemoglobin, albuminuria, and homeostasis model assessment of insulin resistance. bAdjusted
for age, gender, race/ethnicity, smoking, hypertension, diabetes, body mass index, waist circumference, total cholesterol, low-
density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, alcohol consumption, viral hepatitis mark-
ers, homeostasis model assessment of insulin resistance, and albuminuria. cAdjusted for age, gender, race/ethnicity, smoking,
hypertension, diabetes, body mass index, waist circumference, glucose, total cholesterol, low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, triglycerides, alcohol consumption, viral hepatitis markers, glycosylated hemoglobin and
albuminuria. CI, confidence interval; eGFR, estimated glomerular filtration rate; NHANES, National Health and Nutrition Exam-
ination Survey.
Table 4 Association of serum bilirubin concentrations with urinary albumin excretion G30 mg/g in NHANES participants.
Odds ratio (95% CI) p-Value
Whole cohort (ns13,184)
Unadjusted 0.92 (0.75–1.12) 0.40
Multivariate adjusteda 1.26 (1.03–1.54) 0.02
Excluding participants with a serum creatinine
)2.0 mg/dL or bilirubin )1.3 mg/dL (ns12,671)
Unadjusted 0.88 (0.67–1.15) 0.35
Multivariate adjusteda 1.32 (0.95–1.85) 0.09
Non-diabetics (ns11,931)
Unadjusted 1.05 (0.85–1.29) 0.68
Multivariate adjustedb 1.24 (1.01–1.54) 0.04
Diabetics (ns1253)
Unadjusted 1.04 (0.63–1.73) 0.88
Multivariate adjustedc 1.37 (0.76–2.48) 0.30
aAdjusted for age, gender, race/ethnicity, smoking, hypertension, diabetes, body mass index, waist circumference, total cho-
lesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, alcohol consumption, viral hep-
atitis markers, glycosylated hemoglobin, homeostasis model assessment of insulin resistance, and estimated glomerular
filtration rate. bAdjusted for age, gender, race/ethnicity, smoking, hypertension, diabetes, body mass index, waist circumfer-
ence, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, alcohol con-
sumption, viral hepatitis markers, homeostasis model assessment of insulin resistance, and estimated glomerular filtration
rate. cAdjusted for age, gender, race/ethnicity, smoking, hypertension, diabetes, body mass index, waist circumference, glu-
cose, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein-cholesterol, triglycerides, alcohol con-
sumption, viral hepatitis markers, glycosylated hemoglobin, and estimated glomerular filtration rate. CI, confidence interval;
NHANES, National Health and Nutrition Examination Survey.
persons with abnormal albuminuria also had higher
serum GGT activity and higher prevalence of hepatitis
C seropositivity.
When the analyses described above were limited to
persons diagnosed with diabetes (ns1253), serum
total bilirubin concentrations did not change across
categories of eGFR (11.8"4.4 vs. 11.3"3.6 vs.
12.0"3.6 mmol/L from the 1st–3rd eGFR category,
respectively; ps0.95 for trend) and albuminuria
(11.6"3.9 vs. 11.8"3.8 mmol/L normal vs. abnormal
albuminuria; ps0.87).
When we performed a subgroup analysis of partic-
ipants stratified by age groups (Figure 1), serum bili-
rubin concentrations significantly increased across
eGFR categories, i.e., with higher serum bilirubin in
participants with lower eGFR (p-0.05 or less for each
age group). In contrast, serum bilirubin concentra-
tions did not significantly change across albuminuria
categories stratified by age groups (data not shown).
Table 3 shows the association between serum total
bilirubin and eGFR (included as continuous variable)
in univariate and multivariate linear regression mod-
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Figure 1 Mean ("SD) serum bilirubin concentrations by
age and estimated glomerular filtration rate (eGFR) catego-
ries in the NHANES participants (ns13,184).
Differences for trends in serum bilirubin for each age group
were tested by one-way analysis of variance.
els. In univariate analysis, total bilirubin was inversely
associated with eGFR in the whole sample, in the non-
diabetic subgroup, and after excluding subjects with
a serum creatinine )176.8 mmol/L or a total bilirubin
concentration )22.23 mmol/L. No significant associ-
ation was found between serum bilirubin and eGFR
in the diabetic subgroup. These results remained
essentially unchanged after adjustment for demo-
graphics, comorbidities, alcohol consumption, viral
hepatitis status, albuminuria and other laboratory
measures.
Table 4 shows the association between serum total
bilirubin and albuminuria – included as categorical
measure – in unadjusted and fully adjusted logistic
regression models. Serum bilirubin did not correlate
with abnormal albuminuria in unadjusted logistic
regression models, neither in the whole cohort nor in
other subgroups of participants. Conversely, the asso-
ciation between serum bilirubin and abnormal albu-
minuria became significant after adjustment for
demographics, comorbidities, alcohol consumption,
viral hepatitis status, eGFR and other laboratory
measures, both in the whole cohort and in non-
diabetics, but not in diabetic persons.
Discussion
To our knowledge, this is the first population-based
study specifically aimed at examining the association
between serum bilirubin concentrations and kidney
function measures in the general population. In a
nationally representative sample of US adults, we
found a significant, inverse association between
normal serum total bilirubin concentrations and
eGFR. This association was independent of a broad
spectrum of established risk factors and potential
confounders, such as age, gender, race/ethnicity,
smoking status, hypertension, diabetes, BMI, waist
circumference, plasma lipids, glucose, insulin resis-
tance, viral hepatitis status, alcohol consumption, and
albuminuria. Notably, the inverse association
between serum total bilirubin and eGFR was signifi-
cant in non-diabetic individuals and after excluding
participants with laboratory evidence of advanced kid-
ney dysfunction (defined as a serum creatinine con-
centration )176.8 mmol/L) or possible liver disease
(defined as a serum bilirubin concentration )22.23
mmol/L). Similarly, we found a positive, but much
weaker, association between serum total bilirubin and
abnormal albuminuria in the whole cohort and in the
non-diabetic subgroup. In contrast, we did not find
any association between serum bilirubin with eGFR
and albuminuria in diabetic persons.
These findings partly confirm and extend our recent
observations in a large hospital-based sample of 2678
adult outpatients (mean age: 55"18 years; 43%
male), 210 with diabetes (14). In that study, we found
that serum total bilirubin was inversely associated
with eGFR in both non-diabetic (rs–0.17; p-0.0001)
and diabetic patients (rs–0.14; p-0.05). However, no
information was available on albuminuria, comorbi-
dities, alcohol consumption and other important
potential confounders (14).
The lack of a significant association between serum
bilirubin and eGFR or albuminuria observed in dia-
betic individuals of our cohort is in contrast with the
results by Fukui et al. (13). These authors found that
serum total bilirubin was positively associated with
eGFR, and negatively with albuminuria in a hospital-
based sample of 633 Japanese type 2 diabetic
patients (mean age: 64.4"11.5 years; 52% male). In
that study, the inverse association between serum
bilirubin and albuminuria (standardized b-coeffi-
cients–0.19; p-0.0001) was independent of age, gen-
der, duration of diabetes, BMI, smoking status, blood
pressure, plasma lipids and glycosylated hemoglobin.
However, in that study, no adjustment was made for
important confounders, such as eGFR, alcohol con-
sumption and viral hepatitis status (13).
We believe that the apparently discrepant results
regarding an association, if any, between serum bili-
rubin and kidney function measures in the diabetic
population (13, 14) can be largely explained by the
larger sample size of the present study and, princi-
pally, by differences in the study population (for
example, different distribution of age, gender, ethnic-
ity and comorbidities) and study methodology (gen-
eral population vs. hospital-based cohort).
Clearly, we must be cautious in making any causal
inference, given the cross-sectional design of our
study. The exact mechanism(s) linking higher serum
bilirubin and decreased kidney function measures are
not fully understood. The most obvious explanation
for our findings is that the greater prevalence of lower
eGFR in persons with higher serum bilirubin concen-
trations simply reflects the coexistence of established
risk factors for kidney damage. However, since in our
study serum bilirubin was associated with decreasing
eGFR and rising albuminuria independently of several
established risk factors, it is conceivable that serum
bilirubin might confer an excess risk over and above
the risk expected as a result of the established and
more traditional risk factors. In clinical practice, an
increased serum bilirubin concentration is conven-
tionally interpreted as a marker of liver dysfunction,
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including cholestasis, drug-induced hepatitis, viral
hepatitis, Gilbert’s syndrome and others (22). In our
study, however, serum bilirubin was significantly
associated with decreasing eGFR after excluding
subjects with a serum bilirubin concentration
)22.23 mmol/L, and even after adjusting for alcohol
intake and viral hepatitis status. Thus, alcohol con-
sumption, viral hepatitis and other advanced liver dis-
eases are unlikely to fully explain the association of
serum bilirubin concentrations with worsening
kidney function. In addition, as reported previously,
the exclusion of persons with a serum bilirubin
concentration )22.23 mmol/L minimizes any signifi-
cant laboratory interference by bilirubin with the
measurement of serum creatinine.
It could be hypothesized that the bilirubin-kidney
dysfunction association primarily reflects the associ-
ation of serum bilirubin concentrations with non-
alcoholic fatty liver disease (NAFLD). NAFLD is now
regarded as the hepatic manifestation of the meta-
bolic syndrome and represents the most common
cause of mild to moderate increases in serum biliru-
bin and other liver enzymes in Western countries
(23–25). NAFLD can promote atherogenic dyslipide-
mia and contribute to CKD pathogenesis – as well as
to accelerated atherogenesis – through the release of
some pathogenetic mediators from the steatotic liver,
including increased C-reactive protein and other
inflammatory cytokines (26). Importantly, several
studies have shown that these potential mediators of
vascular and kidney damage are markedly higher in
patients with NAFLD than in those without (26–31),
and are thought to be pathogenic factors for the
development of CKD (32–35). Consistent with the
hypothesis that liver inflammation (or other liver-
derived factors) in NAFLD may play a role in kidney
disease progression, it has been shown that type 2
diabetic subjects with chronic hepatitis B virus infec-
tion were more likely to develop end-stage renal dis-
ease compared with those not infected with hepatitis
B virus (36). More importantly, recent studies found
that NAFLD is independently associated with an
increased incidence of CKD in both non-diabetic and
diabetic populations (37, 38).
Limitations of our study include its cross-sectional
design, which allows us to identify associations and
should not yield any conclusions about causation.
Second, NHANES only measured total and not frac-
tionated bilirubin concentrations (thus, excluding the
possibility to discriminate the Gilbert’s disease from
other liver disease), and performed only a single
blood draw for measuring serum bilirubin, perhaps
limiting the precision of the bilirubin measurement.
Third, liver ultrasonography for diagnosing NAFLD
was not performed. Finally, we used the eGFR instead
of a directly measured GFR to assess kidney function.
It is known that current GFR estimates have greater
inaccuracy in populations without known CKD than in
those with kidney disease. Nonetheless, current GFR
estimates facilitate the detection, evaluation, and
management of kidney disease. Also, many organi-
zations recommend the use of prediction equations
for the evaluation of kidney function in large epide-
miologic studies and in clinical practice (18).
Despite these limitations, our analysis has several
important strengths. First, it is the most comprehen-
sive national survey to examine the associations of
serum total bilirubin with kidney function and albu-
minuria in US adults. Second, NHANES used uniform
methods to collect data on demographics, comorbi-
dities and laboratory measures. Third, the extensive
and complete data on important factors associated
with kidney disease and serum bilirubin increases
allows us to give an unbiased estimate for the rela-
tionship between serum bilirubin and CKD. Finally,
with the design of NHANES, we are able to generalize
the results to the entire US civilian non-institutional-
ized population.
In conclusion, our findings suggest that increasing
serum total bilirubin concentrations are independent-
ly associated with decreasing eGFR and increasing
albuminuria in the US adult population. Future pro-
spective studies are required to determine the tem-
poral nature of this association.
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